Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Opthea Limited Sponsored ADR (OPT)
NASDAQ:OPT
OPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.79 - $6.30
Previous CloseN/A
Volume12.29K
Average Volume (3M)38.60K
Market Cap
$779.78M
Enterprise Value$191.88M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Feb 26, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.67
Shares Outstanding153,886,830
10 Day Avg. Volume39,043
30 Day Avg. Volume38,602
Standard Deviation0.19
R-Squared0.07
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6221.34
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.54K
Enterprise Value/Ebitda-0.41
Forecast
1Y Price Target
$12.50Price Target Upside150.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Opthea Limited Sponsored ADR News
PremiumCompany Announcements
Opthea Completes Key Phase 3 Trial Milestone in Wet AMD Treatment
PremiumCompany Announcements
Opthea Unveils Promising Wet AMD Therapy at Investor Day
PremiumCompany Announcements
Opthea’s Innovative Approach to AMD Treatment with Sozinibercept
PremiumCompany Announcements
Opthea to Present Phase 3 Trial Update at J.P. Morgan Healthcare Conference---
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressOpthea has completed the final Wk-52 patient visit in COAST, the first of two Ph3 trials evaluating sozinibercept in wet AMD.
Commercial PotentialOpthea held an investor day highlighting the commercial opportunity for sozinibercept (OPT-302) in wet AMD.
Bears Say
Clinical Trials RisksDelays or unfavorable outcomes from the ongoing clinical trials could affect the company’s valuation.
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
3.32% Other Institutional Investors
96.68% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
OPT FAQ
What was Opthea Limited Sponsored ADR’s price range in the past 12 months?
Opthea Limited Sponsored ADR lowest stock price was $1.79 and its highest was $6.30 in the past 12 months.
What is Opthea Limited Sponsored ADR’s market cap?
Opthea Limited Sponsored ADR’s market cap is $779.78M.
When is Opthea Limited Sponsored ADR’s upcoming earnings report date?
Opthea Limited Sponsored ADR’s upcoming earnings report date is Feb 26, 2025 which is in 5 days.
How were Opthea Limited Sponsored ADR’s earnings last quarter?
Opthea Limited Sponsored ADR released its earnings results on Aug 30, 2024. The company reported -$1.6 earnings per share for the quarter, missing the consensus estimate of -$0.8 by -$0.8.
Is Opthea Limited Sponsored ADR overvalued?
According to Wall Street analysts Opthea Limited Sponsored ADR’s price is currently Undervalued.
Does Opthea Limited Sponsored ADR pay dividends?
Opthea Limited Sponsored ADR does not currently pay dividends.
What is Opthea Limited Sponsored ADR’s EPS estimate?
Opthea Limited Sponsored ADR’s EPS estimate is -0.13.
How many shares outstanding does Opthea Limited Sponsored ADR have?
Opthea Limited Sponsored ADR has 153,886,830 shares outstanding.
What happened to Opthea Limited Sponsored ADR’s price movement after its last earnings report?
Opthea Limited Sponsored ADR reported an EPS of -$1.6 in its last earnings report, missing expectations of -$0.8. Following the earnings report the stock price went up 1.65%.
Which hedge fund is a major shareholder of Opthea Limited Sponsored ADR?
Currently, no hedge funds are holding shares in OPT
---
Opthea Limited Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (150.50% Upside)
$12.50 (150.50% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
91.39%
Trailing 12-Months
Company Description
Opthea Limited Sponsored ADR
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
---
OPT Stock 12 Month Forecast
Average Price Target
$12.50
▲(150.50% Upside)
Technical Analysis
Omeros
―
EyePoint Pharmaceuticals
―
Aldeyra Therapeutics
―
Ocular Therapeutix
―
Arvinas Holding Company
―
Best Analysts Covering OPT
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
+15.54%
reiterated a buy rating 24 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +15.54% per trade.
---